![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
INTERFERON (IFN)-FREE TREATMENT WITH ONCE-DAILY ALISPORIVIR (ALV) ACHIEVES AND MAINTAINS HIGH RATES OF UNDETECTABLE HCV RNA IN A GLOBAL POPULATION OF TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPE (G) 2 OR 3 (VITAL-1 STUDY)
|
|
|
Reported by Jules Levin
Presented at APASL 2012; 16-19 February 2012; Taipei, Taiwan ROC
SK SARIN,1 T PIRATVISUTH,2 WL CHUANG,3 JM PAWLOTSKY,4 R FLISIAK,5 J RASENACK,6 GR FOSTER,7 H WEDEMEYER,8 W ZHANG,9 C AVILA10
1DEPT OF HEPATOLOGY, INSTITUTE OF LIVER AND BILIARY SCIENCES (ILBS), NEW DELHI, INDIA; 2NKC INSTITUTE OF GASTROENTEROLOGY AND HEPATOLOGY, SONGKLANAGARIND HOSPITAL, PRINCE OF SONGKLA HAT YAI, THAILAND; 3KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL,
KAOHSIUNG MEDICAL UNIVERSITY, KAOHSIUNG, TAIWAN; 4UNIVERSITY HOPITAL HENRI MONDOR, CRETEIL, FRANCE; 5MEDICAL UNIVERSITY, BIAYSTOK, POLAND; 6ALBERT LUDWIGS UNIVERSITY, FREIBURG, GERMANY; 7QUEEN MARY, UNIVERSITY OF LONDON, BART'S AND THE LONDON SCHOOL OF MEDICINE, UK; 8DEPT OF GASTROENTEROLOGY, HEPATOLOGY AND ENDOCRINOLOGY, MEDIZINISCHE HOCHSCHULE HANNOVER, HANNOVER, GERMANY; 9BEIJING NOVARTIS PHARMA CO LTD, SHANGHAI, CHINA; 10NOVARTIS PHARMA AG, BASEL, SWITZERLAND
![APSL1.gif](../images/022312/022312-2/APSL1.gif)
![APSL2.gif](../images/022312/022312-2/APSL2.gif)
![APSL3.gif](../images/022312/022312-2/APSL3.gif)
![APSL4.gif](../images/022312/022312-2/APSL4.gif)
![APSL5.gif](../images/022312/022312-2/APSL5.gif)
![APSL6.gif](../images/022312/022312-2/APSL6.gif)
![APSL7.gif](../images/022312/022312-2/APSL7.gif)
![APSL8.gif](../images/022312/022312-2/APSL8.gif)
![APSL9.gif](../images/022312/022312-2/APSL9.gif)
![APSL10.gif](../images/022312/022312-2/APSL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|